[Pharmacological and clinical profile of anti-human IL-6 receptor antibody (tocilizumab, ACTEMRA), a novel therapeutic drug for Castleman's disease].
Ohsugi
Yoshiyuki
Y
ohsugiysy@chugai-pharm.co.jp
Tsuchimoto
Nobuyuki
N
D000818:Animals; D000911:Antibodies, Monoclonal / Q000009:adverse effects / Q000378:metabolism / Q000494:pharmacology / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D001667:Binding, Competitive; D005871:Castleman Disease / Q000188:drug therapy* / Q000209:etiology / Q000473:pathology; D049109:Cell Proliferation / Q000187:drug effects; D002986:Clinical Trials as Topic; D015195:Drug Design; D006801:Humans; D015850:Interleukin-6 / Q000502:physiology; D008198:Lymph Nodes / Q000166:cytology / Q000473:pathology; D019947:Receptors, Interleukin-6 / Q000276:immunology* / Q000378:metabolism; D011994:Recombinant Proteins / Q000627:therapeutic use; D015398:Signal Transduction
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D015850:Interleukin-6; D019947:Receptors, Interleukin-6; D011994:Recombinant Proteins; C502936:tocilizumab